dept header
Directory | Contact
 

Current Grants

  1. Title:American/Australian Mesothelioma Consortium
    Objective:The major goal of this consortium is to combine the efforts of multiple investigators in the United States and Australia in bench work investigations and novel protocols for Malignant Mesothelioma through rapid discovery and eventual validation of markers of early mesothelial carcinogenesis.
    Investigator:Harvey Pass, MD (PI)
    Sponsor: NIH/NCI
  2. Title:Role of Cell Mediators in Asbestos-SV Carcinogenesis
    Objective:The ultimate goal is to reduce the risk of cancer in individuals exposed to asbestos, by targeting the cellular mediators that favor the co-carcinogenic activity of asbestos with SV40.
    Investigator:M. Carbone, PI, Co- investigator, Harvey Pass, MD
    Sponsor:NIH/NCI
  3. Title:Mesothelioma Pathogenesis/ Clinical Core B
    Objective:Accumulation of mesothelioma specimens to be used to develop a successful protocol for harvesting fresh mesothelioma cells from parietal pluera from patients having thoracotomy/thoracoscopy.
    Investigator:Harvey Pass, MD
    Sponsor:NIH/NCI
  4. Title:National Virtual Mesothelioma Data Bank: NMVTB
    Objective:The objective of the National Mesothelioma Virtual Bank (NMVB) for Translational Research is to maximize the effectiveness of data and biospecimen collection for mesothelioma. NMVB will serve as a resource that will allow researchers real time access to clinical data associated with tissue specimens from the registry, thus expanding scientific discovery and effective treatments to benefit the mesothelioma research and patient.
    Investigator:Harvey Pass, MD and Jonathan Melamed, MD
    Sponsor:Center for Disease Control
  5. Title:Identification of genes associated with early stages and progression of asbestos induced pleural malignant mesothelioma
    Objective: Representation Oligonucleotide Microarray Analysis (ROMA) was used as a tool for identification and fine mapping of the chromosomal areas associated with the origin and progression of the asbestos-induced mesothelioma. To complete our search for therapeutical marker and targets, we now plan to produce expression array data and overlay them on the ROMA data with subsequent validation of the selected genes in functional assays on tumorigenicity.
    Investigator: Sergey Ivanov, Ph.D.
    Sponsor: MARF: Mesothelioma Applied Research Foundation
    web site:Curemeso.org
  6. Discovery and Clinical Validation of Cancer Biomarkers Using Printed Glycan Array
    This research is dedicated to the development and clinical validation to a serum-based diagnostic test for early detection of cancer and cancer risk. Specific aims are: (1) To identify, and validate anti-glycan autoantibody signatures of the specific stages of breast cancer disease, including: increased breast cancer risk, pre-invasive (DCIS) and early breast cancer, breast cancer progression; (2) To expand the study to the identification and validation of anti-glycan autoantibody signatures for three other major malignancies, including ovarian, melanoma and Non-Small Cell Lunch Cancer (NSCLC); (3) To identify, isolate and/or synthesize, and perform preliminary testing of novel tumor-associated glycans in serum and cellular materials as cancer-diagnostic antigens.
    Investigator:Margaret E. Huflejt, Ph.D
    Sponsor:National Cancer Institute
  7. The America/Australian Mesothelioma Consortium: Supplement
    Immuno-signatures of Lung Cancer and Lung Cancer risk in population of HIV-infected patients
    Investigator:Harvey I. Pass, M.D.
    Sponsor:National Cancer Institute
  8. American Thoracic Society (ATS)
    The goals of this ongoing research is (1) to identify differences in down-stream gene regulation pathways caused by the over expression ofOPNaandOPNcisoforms through the performance of Affymetrix oligonucleotide cDNA micro array analysis of mRNA from the NSLC cell line forced expression with OPN isoforms and controls; (2) To further explore the functional impact ofOPNaandOPNc, through a series of knockout experiments using sh-RNA in both our experimental and wild type NSCLC cell lines with high endogenous OPN expression and (3)in vivovalidation of differential malignant properties conferred byOPNaandOPNcisoforms NSCLC in mouse xenocraft models of tumor growth and mestastasis formation. The structural similaritiesOPNaandOPNcmay make OPN ideal for isoform-specific target treatment strategies in NSCLC.